To test whether MET pathway activation may serve as a bypass mechanism, [8] we established a patient-derived EGFRamp GBM model (KCI-10-40) with acquired resistance to erlotinib, then measured its sensitivity to MET inhibitor (Fig. 5). Here, MET is linked to glioblastoma.